BIOMAT Database Logo BIOMAT Database Logo

Successful treatment of cytomegalovirus disease with 9-(1,3-dihydroxy-2-propoxymethyl guanine). 1988

B de Hemptinne, and M E Lamy, and M Salizzoni, and C Cornu, and J Mostin, and J Fevery, and V De Groote, and J B Otte
Department of Surgery, University of Louvain Medical School, Brussels, Belgium.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D003587 Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS. Herpesvirus 5, Human,Human Herpesvirus 5,Salivary Gland Viruses,HHV 5,Herpesvirus 5 (beta), Human,Cytomegaloviruses,Salivary Gland Virus,Virus, Salivary Gland,Viruses, Salivary Gland
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000212 Acyclovir A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. Acycloguanosine,9-((2-Hydroxyethoxy)methyl)guanine,Aci-Sanorania,Acic,Aciclobeta,Aciclostad,Aciclovir,Aciclovir Alonga,Aciclovir-Sanorania,Acifur,Acipen Solutab,Acivir,Activir,Acyclo-V,Acyclovir Sodium,Antiherpes Creme,Avirax,Cicloferon,Clonorax,Cusiviral,Genvir,Herpetad,Herpofug,Herpotern,Herpoviric,Isavir,Laciken,Mapox,Maynar,Milavir,Opthavir,Supraviran,Viclovir,Vipral,Virax-Puren,Virherpes,Virmen,Virolex,Virupos,Virzin,Wellcome-248U,Zoliparin,Zovirax,Zyclir,aciclovir von ct,Aci Sanorania,Aciclovir Sanorania,Acyclo V,Alonga, Aciclovir,Sodium, Acyclovir,Solutab, Acipen,Virax Puren,ViraxPuren,Wellcome 248U,Wellcome248U
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D014775 Virus Activation The mechanism by which latent viruses, such as genetically transmitted tumor viruses (PROVIRUSES) or PROPHAGES of lysogenic bacteria, are induced to replicate and then released as infectious viruses. It may be effected by various endogenous and exogenous stimuli, including B-cell LIPOPOLYSACCHARIDES, glucocorticoid hormones, halogenated pyrimidines, IONIZING RADIATION, ultraviolet light, and superinfecting viruses. Prophage Excision,Prophage Induction,Virus Induction,Viral Activation,Activation, Viral,Activation, Virus,Activations, Viral,Activations, Virus,Excision, Prophage,Excisions, Prophage,Induction, Prophage,Induction, Virus,Inductions, Prophage,Inductions, Virus,Prophage Excisions,Prophage Inductions,Viral Activations,Virus Activations,Virus Inductions

Related Publications

B de Hemptinne, and M E Lamy, and M Salizzoni, and C Cornu, and J Mostin, and J Fevery, and V De Groote, and J B Otte
Cytomegalovirus infection, 9-(1,3-Dihydroxy-2-propoxymethyl)guanine, and Crohn's disease.
August 1986, Annals of internal medicine,
B de Hemptinne, and M E Lamy, and M Salizzoni, and C Cornu, and J Mostin, and J Fevery, and V De Groote, and J B Otte
Breakthrough of cytomegalovirus infection despite 9-(1,3-dihydroxy-2-propoxymethyl)guanine therapy.
April 1986, Annals of internal medicine,
B de Hemptinne, and M E Lamy, and M Salizzoni, and C Cornu, and J Mostin, and J Fevery, and V De Groote, and J B Otte
Treatment of cytomegalovirus infections in renal transplant recipients with 9-(1,3-dihydroxy-2-propoxymethyl) guanine.
June 1988, Transplantation,
B de Hemptinne, and M E Lamy, and M Salizzoni, and C Cornu, and J Mostin, and J Fevery, and V De Groote, and J B Otte
Treatment of cytomegalovirus retinitis in a patient with AIDS with 9-(1,3-dihydroxy-2-propoxymethyl)guanine.
February 1987, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie,
B de Hemptinne, and M E Lamy, and M Salizzoni, and C Cornu, and J Mostin, and J Fevery, and V De Groote, and J B Otte
[Ganciclovir [9-(1,3-dihydroxy-2-propoxymethyl)] guanine. A new antiviral agent against Cytomegalovirus].
August 1989, Ugeskrift for laeger,
B de Hemptinne, and M E Lamy, and M Salizzoni, and C Cornu, and J Mostin, and J Fevery, and V De Groote, and J B Otte
Fine structure of cells infected with human cytomegalovirus after treatment with 9-(1,3-dihydroxy-2-propoxymethyl)guanine.
June 1987, The Journal of general virology,
B de Hemptinne, and M E Lamy, and M Salizzoni, and C Cornu, and J Mostin, and J Fevery, and V De Groote, and J B Otte
Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine.
October 1985, The Journal of infectious diseases,
B de Hemptinne, and M E Lamy, and M Salizzoni, and C Cornu, and J Mostin, and J Fevery, and V De Groote, and J B Otte
9-(1,3-Dihydroxy-2-propoxymethyl)guanine (ganciclovir) in the treatment of cytomegalovirus gastrointestinal disease with the acquired immunodeficiency syndrome.
August 1987, Annals of internal medicine,
B de Hemptinne, and M E Lamy, and M Salizzoni, and C Cornu, and J Mostin, and J Fevery, and V De Groote, and J B Otte
Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro.
October 1983, Antimicrobial agents and chemotherapy,
B de Hemptinne, and M E Lamy, and M Salizzoni, and C Cornu, and J Mostin, and J Fevery, and V De Groote, and J B Otte
Effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men.
January 1986, Annals of internal medicine,
Copied contents to your clipboard!